1. Nigella sativa L. and its bioactive and nutraceutical components in the management of diabetic peripheral neuropathy.
- Author
-
Khodaie SA, Razavi R, Nikkhah H, Namiranian N, and Kamalinejad M
- Subjects
- Humans, Animals, Oxidative Stress drug effects, Anti-Inflammatory Agents pharmacology, Diabetic Neuropathies drug therapy, Diabetic Neuropathies metabolism, Nigella sativa chemistry, Dietary Supplements, Hypoglycemic Agents pharmacology, Hypoglycemic Agents therapeutic use, Antioxidants pharmacology, Plant Extracts pharmacology
- Abstract
Diabetes-induced hyperglycemia leads to excessive production of oxygen free radicals, inflammatory cytokines, and oxidative stress, which initiates diabetic peripheral neuropathy (DPN). Currently, this condition affects 20% of adults with diabetes. Despite significant advances in the treatment of diabetes, the incidence of its complications, including DPN, is still high. Thus, there is a growing research interest in developing more effective and treatment approaches with less side effects for diabetes and its complications. Nigella sativa L. (NS) has received much research attention as an antioxidant, anti-yperglycemic factor, and anti-inflammatory agent. This natural compound demonstrates its antidiabetic neuropathy effect through various pathways, including the reduction of lipid peroxidation, the enhancement of catalase and superoxide dismutase enzyme activity, and the decrease in inflammatory cytokine levels. The present review focuses on the bioactive and nutraceutical components of black cumin (Nigella sativa L.) and their effects on DPN. In addition, we have also summarized the findings obtained from several experimental and clinical studies regarding the antidiabetic neuropathy effect of NS in animal models and human subjects., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF